Drugs

Telaprevir (marketed as Incivek) Information

The U.S. Food and Drug Administration (FDA) has received reports of serious skin reactions, some fatal, in patients taking the hepatitis C drug Incivek (telaprevir) in combination with the drugs peginterferon alfa and ribavirin. Significantly, some patients died when they continued to receive Incivek combination treatment after developing a worsening, or progressive rash and systemic symptoms (symptoms affecting the entire body). As a result, FDA is adding a boxed warning to the Incivek drug label stating that Incivek combination treatment and any other drugs also suspected to contribute to serious skin reaction must be immediately stopped in patients experiencing a progressive severe rash alone or along with systemic body symptoms.

Contact FDA

For More Info
855-543-DRUG (3784)
and press 1
Report a Serious Problem to MedWatch

Complete and submit the report Online.

Download form or call 1-800-332-1088 to

request a reporting form, then complete
and return to the address on the
pre-addressed form, or submit by fax to
1-800-FDA-0178.

Page Last Updated: 07/15/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.